Radioligand Therapy Beyond Neuroendocrine Tumours: Dosimetry, Supply Chain and Access
DOI:
https://doi.org/10.5281/zenodo.22649084Keywords:
Radioligand Therapy Beyond Neuroendocrine Tumours, Translational medicine; Evidence synthesis;, Clinical implementation; Health services researchAbstract
Radioligand Therapy Beyond Neuroendocrine Tumours is an area of active development in translational medicine, with evidence
that has accumulated unevenly across its component questions. We review the current evidence base for radioligand therapy
beyond neuroendocrine tumours, spanning analytical, clinical, implementation, governance, and economic dimensions, focusing
on where practice has converged and where it continues to vary, and set out the practical considerations relevant to a service
considering its adoption. We conclude that selective, context-specific use is best supported by the evidence currently available,
rather than uniform adoption or avoidance.
References
Alvez D, Dumitrescu A, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.2196/69678
Brankovic K, Kowalczyk B, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.7759/cureus.46454
Castellani R, Ristic C, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.1016/j.ssci.2025.107028
Dumitrescu A, Andric D, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.2196/48633
Eriksdottir B, Brankovic E, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.1371/journal.pone.0305949
Farkas I, Ionescu F, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.1371/journal.pdig.0000514
Grabowski P, Petrescu G, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.17219/acem/208596
Hendriksen W, Wojcik H, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.7759/cureus.104086
Ionescu F, Foscarini I, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.1038/s41746-023-00852-5
Jankowiak G, Grabowski J, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.1016/j.mayocpiqo.2022.09.004
Kowalczyk N, Novotna K, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.1177/08404704241291226
Lindqvist U, Urbanek L, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.1093/medlaw/fwad013
Marchetti D, Doncheva M, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.2196/89834
Novotna E, Eriksdottir N, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.1007/s10916-024-02104-9
Ostrowski L, Lindqvist O, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.3389/fdgth.2026.1896184
Petrescu S, Szabo P, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.3390/diagnostics15162117
Quintero B, Balogh Q, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.4103/jrpp.jrpp_20_65
Ristic C, Castellani R, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.3389/fdgth.2026.1763884
Szabo J, Jankowiak S, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.2196/48297
Tarasov Q, Quintero T, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.1007/s00330-025-12031-z
Urbanek Z, Zielinski U, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.3389/fdgth.2026.1699005
Vasquez A, Alvez V, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.3389/fdgth.2026.1834800
Wojcik H, Hendriksen W, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.2196/69678
Zielinski O, Ostrowski Z, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.7759/cureus.46454
Andric V, Vasquez A, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.1016/j.ssci.2025.107028
Balogh E, Emmerich B, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.2196/48633
Chiriac F, Farkas C, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.1371/journal.pone.0305949
Doncheva M, Marchetti D, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a validation study". Trials 22(2017): 377-383. DOI: 10.1371/journal.pdig.0000514
Emmerich T, Tarasov E, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.17219/acem/208596
Foscarini C, Chiriac F, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.7759/cureus.104086
Alvez D, Dumitrescu A, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.1038/s41746-023-00852-5
Brankovic K, Kowalczyk B, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.1016/j.mayocpiqo.2022.09.004
Castellani R, Ristic C, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.1177/08404704241291226
Dumitrescu A, Andric D, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.1093/medlaw/fwad013
Eriksdottir B, Brankovic E, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.2196/89834
Farkas I, Ionescu F, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.1007/s10916-024-02104-9
Grabowski P, Petrescu G, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.3389/fdgth.2026.1896184
Hendriksen W, Wojcik H, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.3390/diagnostics15162117
Ionescu F, Foscarini I, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a scoping review". JAMA 44(2020): 498-506. DOI: 10.4103/jrpp.jrpp_20_65
Jankowiak G, Grabowski J, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.3389/fdgth.2026.1763884
Kowalczyk N, Novotna K, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.2196/48297
Lindqvist U, Urbanek L, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.1007/s00330-025-12031-z
Marchetti D, Doncheva M, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.3389/fdgth.2026.1699005
Novotna E, Eriksdottir N, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.3389/fdgth.2026.1834800
Ostrowski L, Lindqvist O, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.2196/69678
Petrescu S, Szabo P, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.7759/cureus.46454
Quintero B, Balogh Q, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.1016/j.ssci.2025.107028
Ristic C, Castellani R, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.2196/48633
Szabo J, Jankowiak S, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.1371/journal.pone.0305949
Tarasov Q, Quintero T, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.1371/journal.pdig.0000514
Urbanek Z, Zielinski U, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.17219/acem/208596
Vasquez A, Alvez V, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.7759/cureus.104086
Wojcik H, Hendriksen W, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.1038/s41746-023-00852-5
Zielinski O, Ostrowski Z, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.1016/j.mayocpiqo.2022.09.004
Andric V, Vasquez A, et al. "Radioligand Therapy Beyond Neuroendocrine Tumours: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.1177/08404704241291226
